Retreatment With Radium-223 Found Safe in mCRPC
Wednesday, 1st June 2016
Luke Nordquist, MD, discusses a study investigating a higher dose of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and the ongoing potential of the agent in treating the disease.
This article was picked up by Colin Hubball - thanks Colin !
Voluntary Services Exhibition for Trainee GPs
28 Mar 2019 13:30–14:45
PSA Testing Chester Masonic Hall Christleton
30 Mar 2019 09:30–12:30
PSA Testing at Nantwich Civic Hall
13 Apr 2019 09:30–12:30
Wellbeing Event for NHS staff
1 May 2019 10:00–15:00
Group AGM at Leighton Hospital, Crewe
11 May 2019 10:00–12:00
New Podcast from Pain Concern
11 Mar 2019